Human orthopneumovirus

DGAP-News: Publication in PNAS unveils molecular pathway required for influenza virus replication with large potential as an antiviral drug target

Tuesday, June 30, 2020 - 2:10pm

[1] , [2] The research identifies and confirms the full molecular chain of events connecting the virus-activated Raf/MEK/ERK signalling pathway via its downstream target RSK to the final export of vRNPs during an influenza virus infection.

Key Points: 
  • [1] , [2] The research identifies and confirms the full molecular chain of events connecting the virus-activated Raf/MEK/ERK signalling pathway via its downstream target RSK to the final export of vRNPs during an influenza virus infection.
  • As the virus is unable to perform this function by itself, this represents an Achilles heel of virus replication.
  • [3]
    "By targeting the enzyme MEK, an essential component of the signalling cascade, ATR-002 inhibits this pathway and, thus, leads to a blockade of viral replication.
  • This pathway is central for replication of many RNA viruses, such as the influenza virus, hantavirus or respiratory syncytial virus (RSV) and also SARS-CoV-2, the virus that causes COVID-19.

Global Respiratory Syncytial Virus Diagnostics Market 2020-2024 | Evolving Opportunities with Abbott Laboratories and Becton, Dickinson and Co. | Technavio

Friday, June 26, 2020 - 9:00am

The global respiratory syncytial virus diagnostics market is expected to grow by USD 585.17 million as per Technavio.

Key Points: 
  • The global respiratory syncytial virus diagnostics market is expected to grow by USD 585.17 million as per Technavio.
  • View the full release here: https://www.businesswire.com/news/home/20200626005014/en/
    Technavio has announced its latest market research report titled Global Respiratory Syncytial Virus (RSV) Diagnostics Market 2020-2024 (Graphic: Business Wire).
  • In addition, technological advancements are anticipated to boost the growth of the respiratory syncytial virus diagnostics market.
  • These factors are expected to fuel the growth of the global respiratory syncytial virus diagnostics market during the forecast period.

Adamis Pharmaceuticals Announces License to Commercialize Tempol, a Novel Investigational Anti-inflammatory and Antioxidant Drug for the Treatment of Respiratory Diseases Including COVID-19

Monday, June 15, 2020 - 2:00pm

SAN DIEGO, June 15, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (Adamis) announced today a license to commercialize Tempol, a novel patented investigational drug for the treatment of Coronavirus (COVID-19).

Key Points: 
  • SAN DIEGO, June 15, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (Adamis) announced today a license to commercialize Tempol, a novel patented investigational drug for the treatment of Coronavirus (COVID-19).
  • The license includes the worldwide use of Tempol for the treatment of all respiratory diseases including asthma, respiratory syncytial virus, influenza and COVID-19.
  • In addition, the exclusive license includes the use of Tempol for reducing radiation dermatitis in patients undergoing treatment for cancer.
  • In severe cases, this can progress to pneumonia, acute respiratory distress syndrome (ARDS), acute cardiac injury and eventually death.

Global Market for Respiratory Syncytial Virus (RSV) Diagnostics: Increase in Product Launches and Support Initiatives from Regulatory Bodies Driving Market Growth - ResearchAndMarkets.com

Wednesday, May 20, 2020 - 5:36pm

The respiratory syncytial virus diagnostics market is poised to grow by $ 585.17 million during 2020-2024 progressing at a CAGR of 10% during the forecast period.

Key Points: 
  • The respiratory syncytial virus diagnostics market is poised to grow by $ 585.17 million during 2020-2024 progressing at a CAGR of 10% during the forecast period.
  • The report on the respiratory syncytial virus diagnostics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
  • The market is driven by the increase in product launches, government and non-profit organization initiatives to diagnose RSV, and growing number of M&A.
  • This study identifies the technological advancements as one of the prime reasons driving the respiratory syncytial virus diagnostics market growth during the next few years.

Analysis on Impact of Covid-19- Global Respiratory Syncytial Virus Diagnostics Market 2020-2024 | Evolving Opportunities with Abbott Laboratories and Becton, Dickinson and Co. | Technavio

Wednesday, May 13, 2020 - 7:30am

The global respiratory syncytial virus diagnostics market is expected to grow by USD 585.17 million as per Technavio.

Key Points: 
  • The global respiratory syncytial virus diagnostics market is expected to grow by USD 585.17 million as per Technavio.
  • The use of such RSV diagnostic products for COVID-19 testing is expected to fuel the growth of the RSV diagnostics market.
  • In addition, technological advancements are anticipated to boost the growth of the respiratory syncytial virus diagnostics market.
  • These factors are expected to fuel the growth of the global respiratory syncytial virus diagnostics market during the forecast period.

Vaxxel Acquires Transgene's DuckCelt®-T17 Cell Line to Develop Industrial-scale Vaccines Against Respiratory Viruses

Monday, May 4, 2020 - 7:00am

Vaxxel SAS, a French start-up, developing vaccines against respiratory viral infections, announces the acquisition of Transgenes (Paris:TNG) proprietary DuckCelt-T17 cell line.

Key Points: 
  • Vaxxel SAS, a French start-up, developing vaccines against respiratory viral infections, announces the acquisition of Transgenes (Paris:TNG) proprietary DuckCelt-T17 cell line.
  • It will allow us to continue developing our vaccines against respiratory viruses namely a monovalent vaccine against human Metapneumovirus and a bivalent one against Respiratory Syncytial Virus and human Metapneumovirus.
  • We are glad to valorize an asset such as our DuckCelt-T17 cell line with Vaxxels high potential projects.
  • Vaxxel develops live-attenuated vaccines against Metapneumovirus and against the Respiratory Syncytial Virus based on the Metavac vaccine platform.

Insights into the Global Respiratory Syncytial Virus Therapeutics Market (2018 to 2026) - Featuring AstraZeneca, AbbVie & F. Hoffmann-La Roche Among Others - ResearchAndMarkets.com

Monday, March 30, 2020 - 11:02am

The "Global Respiratory Syncytial Virus Therapeutics Market Analysis 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Respiratory Syncytial Virus Therapeutics Market Analysis 2019" report has been added to ResearchAndMarkets.com's offering.
  • The Respiratory Syncytial Virus Therapeutics market is expected to reach $2,958.92 million by 2026 growing at a CAGR of 13.4% from 2018 to 2026.
  • Respiratory syncytial virus (RSV) is a common and contagious virus that infects the respiratory tract of children and adults.
  • No specific approved drug or vaccine has been available to treat or prevent RSV infection to date.

Asia-Pacific Respiratory Syncytial Virus (RSV) Market to 2028 - Featuring AstraZeneca, Bavarian Nordic & Enanta Pharmaceuticals Among Others - ResearchAndMarkets.com

Friday, March 27, 2020 - 1:37pm

Human Respiratory Syncytial Virus (RSV) is an enveloped, single-stranded, negative-sense RNA orthopneumovirus belonging to the family of Pneumoviridae.

Key Points: 
  • Human Respiratory Syncytial Virus (RSV) is an enveloped, single-stranded, negative-sense RNA orthopneumovirus belonging to the family of Pneumoviridae.
  • Respiratory Syncytial Virus (RSV) is the leading cause of lower respiratory tract infections (LRTIs) in infants, with a peak age of hospitalization between 2-3 months of age.
  • Respiratory Syncytial Virus (RSV) is also an important cause of hospitalizations and deaths in elderly adults.
  • It is likely that several first-in-class products for the management of Respiratory Syncytial Virus (RSV) will coexist simultaneously by 2028, including both vaccines and antivirals for treatment of severe or breakthrough Respiratory Syncytial Virus (RSV) infections.

2020 Global Respiratory Syncytial Virus Diagnostics Market: DNA Probes, Monoclonal Antibodies, Immunoassays, IT & Other Technologies - ResearchAndMarkets.com

Tuesday, January 28, 2020 - 3:47pm

The report presents a detailed analysis of the Respiratory Syncytial Virus diagnostics market in the US, Europe, (France, Germany, Italy, Spain, UK) and Japan.

Key Points: 
  • The report presents a detailed analysis of the Respiratory Syncytial Virus diagnostics market in the US, Europe, (France, Germany, Italy, Spain, UK) and Japan.
  • Current scientific views on the Respiratory Syncytial Virus definition, epidemiology and etiology are reviewed.
  • The report provides the 5-year test volume and sales forecasts by country for the following market segments:
    For each country, in addition to test volume and sales projections, the report presents sales and market share estimates for major suppliers of Respiratory Syncytial Virus tests.
  • Also, the report examines the market applications of DNA Probes, Monoclonal Antibodies, Immunoassays, IT and other technologies; reviews features and operating characteristics of automated analyzers; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies emerging business expansion opportunities, alternative market penetration strategies, market entry barriers and risks, and strategic planning issues and concerns.

Meissa Vaccines Receives U.S. FDA Fast Track Designation for Respiratory Syncytial Virus Vaccine, MV-012-968

Friday, January 10, 2020 - 1:00pm

Meissa Vaccines (Meissa), a biotechnology company developing vaccines to prevent viral respiratory infections, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to MV-012-968, an investigational, live attenuated vaccine for protection against respiratory syncytial virus (RSV) infection.

Key Points: 
  • Meissa Vaccines (Meissa), a biotechnology company developing vaccines to prevent viral respiratory infections, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to MV-012-968, an investigational, live attenuated vaccine for protection against respiratory syncytial virus (RSV) infection.
  • With Fast Track Designation, Meissa is eligible for early and frequent interactions with FDA reviewers to discuss all aspects of the clinical development plan for MV-012-968, ensuring that the appropriate data are collected to support an application for vaccine licensure.
  • The frequency of communication granted by Fast Track Designation assures that questions and issues are resolved quickly, often leading to earlier approval and access by patients.
  • Fast Track Designation of MV-012-968 accelerates our ability to develop a much-needed RSV vaccine, said Martin Moore, Ph.D., cofounder and CEO of Meissa.